<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Future 'Exceedingly Bright' for Kidney Stone Prevention

Default sub title

minute read

by Medscape | September 13, 2021
placeholder

"The majority of patients who received lumasiran had normal or near-normal levels after 6 months of treatment," those investigators report.

Topics: Press Coverage